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In spite of great advances in cancer therapy, there is considerable current interest in developing anticancer agents with a new mode of action
because of the development of resistance by cancer cells towards current anticancer drugs. A growing number of studies have shown that some of
the cationic antimicrobial peptides (AMPs), which are toxic to bacteria but not to normal mammalian cells, exhibit a broad spectrum of cytotoxic
activity against cancer cells. Such studies have considerably enhanced the significance of AMPs, both synthetic and from natural sources, which
have been of importance both for an increased understanding of the immune system and for their potential as clinical antibiotics. The electrostatic
attraction between the negatively charged components of bacterial and cancer cells and the positively charged AMPs is believed to play a major
role in the strong binding and selective disruption of bacterial and cancer cell membranes, respectively. However, it is unclear why some host
defense peptides are able to kill cancer cells when others do not. In addition, it is not clear whether the molecular mechanism(s) underlying the
antibacterial and anticancer activities of AMPs are the same or different. In this article, we review various studies on different AMPs that exhibit
cytotoxic activity against cancer cells. The suitability of cancer cell-targeting AMPs as cancer therapeutics is also discussed.
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Despite recent advances in treatment modalities, cancer
remains a major source of morbidity and mortality throughout
the world. In the United States, cancer is the leading cause of
death for individuals less than 85 years of age [1]. Moreover, the
incidence of many cancers, including cancers of the skin,
prostate, breast, and kidney, continues to increase [2]. “Cancer”
is, in fact, a general term that refers to over 100 distinct diseases
affecting many different tissues and cell types. However,
all forms of cancer are characterized by abnormal cell
growth resulting from a relatively small number of inherited
or environmentally-induced genetic mutations [3]. Hanahan and
Weinberg [4] have argued that in order for a cell to become
cancerous, it must acquire six unique traits as a result of altered
cell physiology. These defining traits of cancer cells are: (1) the
ability to generate their own growth signals or respond to weak
growth signals that are ignored by healthy cells; (2) insensitivity
to antiproliferative signals; (3) resistance to cellular suicide
mechanisms that normally cause aberrant cells to die by
apoptosis; (4) the capacity for limitless replication; (5) the
ability to stimulate new blood vessel development in order to
allow for tumour growth; and (6) the capacity to invade tissues,
at first locally, and later to spread or metastasize throughout theTable 1
Summary of select naturally occurring cationic antimicrobial peptides with anticanc
Peptide Source Primary amino acid sequence a
BMAP-28 Bos taurus GGLRSLGRKILRAWKKYGPIIV
HNP-1 (β-defensin) Homo sapiens AC1YC2RIPAC3IAGERRYGTC2
Lactoferricin B Bos taurus FKC1RRWQWRMKKLGAPSIT
LL-37 Homo sapiens LLGDFFRKSKEKIGKEFKRIVQ
Magainin 2 Xenopus laevis GIGKFLHSAKKFGKAFVGEIM




a Amino acid sequences are given in one-letter code. Subscripts indicate pairings o
residues.
b At neutral pH.
c Phospholipase A2.
d Phospholipase D.body. Although localized cancers can often be successfully
treated by surgery and/or radiation therapy, chemotherapy
remains the usual treatment of choice for advanced or metastatic
disease [5]. However, the use of conventional chemotherapeutic
agents that typically target rapidly dividing cancer cells is often
associated with deleterious side-effects caused by inadvertent
drug-induced damage to healthy cells and tissues [6,7].
Moreover, cancer cells that are quiescent or slowly proliferating
are refractory to the cytotoxic effect of chemotherapeutic drugs
that act at the level of DNA synthesis [8]. Cancer cells also
frequently become resistant to chemotherapy as a consequence
of cellular changes that include increased expression of drug-
detoxifying enzymes and drug transporters, altered interactions
between the drug and its target, an increased ability to repair
DNA damage, and defects in the cellular machinery that
mediate apoptosis [9]. The development of a new class of anti-
cancer drugs that lack the toxicity of conventional chemo-
therapeutic agents and are unaffected by common mechanisms
of chemoresistance would be a major advance in cancer treat-
ment. In this article, we review the recent studies on naturally
occurring, as well as some selected hybrid and synthetic
cationic antimicrobial peptides (AMPs) that exhibit anticancer
activities. The biochemical properties and anticancer activities
of some of these AMPs are summarized in Table 1.er activities
Class Net b Anticancer activity
PIIRI α-Helix +7 Membranolytic
IYQGRLWAFC3C1 β-Sheet +3 Membranolytic
Antiangiogenic?
C1VRRAF β-Sheet +8 Membranolytic
Apoptosis inducer
Antiangiogenic
RIKDFLRNLVPRTES α-Helix +6 Membranolytic
NS α-Helix +3 Membranolytic
Apoptosis inducer?










f Cys residues that form disulfide bonds. Boldface indicates cationic amino acid
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Naturally occurring AMPs probably represent one of the first
evolved and successful forms of chemical defense of eukaryotic
cells against bacteria, protozoa, fungi, and viruses [10]. AMPs
have been found in every species that has been tested, including
bacteria, fungi, plants, and animals. A very large number of
AMPs isolated from nature and thousands of synthetic variants
have been found to have a broad spectrum of antimicrobial
activities. For a regularly updated list of plant and animal AMPs,
see the websites: http://www.bbcm.univ.trieste.it/~tossi/antimic.
html and http://aps.unmc.edu/AP/main.php. Most AMPs kill
both Gram-positive and Gram-negative bacteria, while a sig-
nificant number of these bactericidal peptides have been shown
to have anticancer and antiviral activities [10,11]. Some of these
peptides have been found to have lipopolysaccharide (LPS)
neutralizing ability and the capacity to recruit the adaptive
immune response [12]. The growing problem of resistance to
conventional antibiotics is a global public health problem and
the need for new antibiotics has stimulated interest in the
development of AMPs as human therapeutics [13]. Several
AMPs have already entered pre-clinical and clinical trials to
promote wound healing and for the treatment of cystic fibrosis,
catheter site infections, acne, and patients undergoing stem cell
transplantation [14–16].
In addition to antibacterial activities of AMPs, recent studies
on their anticancer activities are exciting and are most relevant
for this review [17]. While not all AMPs are able to kill cancer
cells, those that do can be placed into two broad categories: (a)
AMPs that are highly potent against bacteria and cancer cells
but not against normal mammalian cells and (b) AMPs that are
cytotoxic for bacteria, cancer cells, and normal mammalian
cells. The structural and functional properties of AMPs are
briefly outlined below.
Although the amino acid sequences of different AMPs are
highly heterogeneous and a great variation in their secondary
structures has been reported. AMPs are generally cationic (i.e.,
the net charge at neutral pH varies from +2 to +9) and
amphipathic, which enables the peptides to interact with and
disrupt lipid membranes. Most AMPs are very short in length,
containing 5 to 40 amino acid residues, while a few of them
contain more than 40 residues. Positively charged residues
such as Lys and Arg and substantial hydrophobic residues
(∼30% or more) are commonly found in these peptides. An
important set of AMPs, such as tritrpticin, lactoferricins and
indolicidin, are rich in Trp and Arg residues [18]. Studies have
shown that all-D-amino-acid analogs have identical activity
but opposite chirality relative to natural all-L-peptides; this
property has been utilized in designing AMPs that can resist
proteolytic degradation. Unlike currently available conven-
tional antibiotics, which typically interact with a specific target
protein, most of these cationic AMPs target the cell membrane
of invading microorganisms, leading to cell lysis and death
[10,18,19,20]. Thus, AMPs offer the possibility of a new class
of therapeutics agents, which are complementary to existing
antibiotics, and to which bacteria may not be able to develop
resistance.Most of the linear AMPs are unstructured in solution (an
exception is LL37, a human antimicrobial peptide [20,21]),
while the cyclic peptides due to the presence of one or more
Cys–Cys disulfide bonds form β-sheets [22]. The amphipathi-
city of AMPs is enhanced upon the induction of specific
secondary structures, such as α-helices, β-sheets, or extended
polyproline-like helices; this amphipathicity is thought to play a
key role in their antimicrobial mechanism of action. The
mechanism by which an AMP executes its function depends on
a number of physicochemical properties: the amino acid se-
quence, net charge, amphipathicity, hydrophobicity, structural
folding (includes secondary structure, dynamics and orienta-
tion) in membranes, oligomerization, peptide concentration, and
membrane composition [19]. There are several mechanisms of
membrane-disruption proposed to explain the activity of AMPs
(Fig. 1). Some of the models used to identify the membrane-
disrupting process are carpet model [23], barrel-stave model
[19], toroidal-pore wormhole model [24], and detergent-type
membrane lytic mechanism [25,26]. In the carpet model, AMPs
assemble on the surface of the membrane to disrupt the
membrane via barrel-stave, toroidal-pore, or detergent-type
mechanisms. In the barrel-stave model [19,27–31], AMPs
insert with a transmembrane orientation in membranes and
aggregate to form a traditional ion-channel pore. In the toroidal-
pore model [24,32], the peptides are located closer to the head
group region with an initial orientation parallel to the lipid
bilayer surface. In this orientation, the hydrophilic side of the
helix is exposed to the hydrophilic lipid head groups and the
water phase outside bilayers, while the hydrophobic face of the
helix is buried in the hydrophobic core of the membrane to
minimize the net free energy of folding process. Aggregation of
peptides to a sufficient local concentration increases the curva-
ture strain on the membrane surface to extent that toroidal-pores
form. In the detergent-type mechanism [26], the peptides first
carpet the surface of the lipid bilayer like the beginning stages of
the toroidal-pore model. Following this step, the peptide aggre-
gation leads to a sufficient high local concentration where the
amphipathic nature of the peptide allows them to behave like
detergents and break the lipid membrane into small fragments.
These fragments can be like bicelles or micelles [20]. There are
other models such as the sinking raft model [33] or the mole-
cular electroporation [34], which have not received much
attention in the field, but could be useful to explain the anti-
microbial activity of certain AMPs. In the sinking raft model,
AMPs bound to the cell membrane introduce a large membrane
curvature due to a mass imbalance, which make AMPs sink and
generate transient pores in membranes. On the other hand, in the
molecular electroporation model, AMPs create a difference in
the electrical potential across the membrane leading to pore
formation through electroporation.
Bacterial membranes are negatively charged with lipids such
as phosphatidylglycerol (PG), cardiolipin (CL), or phosphati-
dylserine (PS). Electrostatic interaction between these nega-
tively charged lipids and the positively charged AMPs enable
the cationic peptides to bind bacterial membranes. The outer
membrane of a Gram-negative bacteria is also negatively
charged as it contains anionic lipopolysaccharides (LPS); LPS
Fig. 1. Models of AMP-induced membrane permeabilization. Cationic linear antimicrobial peptides are initially unstructured monomers (most AMPs) or helical and
aggregated (for example, LL-37) in aqueous solution. They bind to negatively charged membrane surface by electrostatic interactions. In the carpet model, peptides
bind to phospholipid head groups and align themselves parallel to the membrane surface in a carpet-like fashion until a critical threshold concentration is reached. In
the barrel stave model, peptides self aggregate in the membrane once a critical threshold concentration of peptide is reached, resulting in the formation of a
transmembrane pore lined by peptide oriented such that the hydrophilic face forms the inner channel while the hydrophobic face is on the outside. Since an AMP has to
span the entire thickness of the lipid bilayer in this model, a minimum of ∼20 residues for α-helical peptide and ∼8 residues for a β-sheet peptide is required to
function via the barrel stave mechanism. The toroidal pore model is an extension of the barrel stave model and postulates that at some critical concentration of peptide
curvature strain induces the membranes to curve inward, resulting in the formation of a pore that is lined by both peptide and lipid headgroups. Repulsive interactions
between the positively charged residues of the peptide are minimized due to the presence of the negatively charged phospholipids in the pore-lining. While the
formation of these pores depend on the lipid:peptide ration and the ionic selectivity depend on the membrane composition, the lifetime of these pores seem to vary. The
detergent-like model proposes that peptides intercalate in between the phospholipid head groups in a cone-like fashion causing curvature strain and micellization at
local regions of high peptide density or when preformed peptide aggregates interact with lipid membranes. Recent NMR studies suggested that after sufficient time
(may be a month or longer) AMPs fragment the lipid bilayers (even those containing toroidal pores) to form bicelle or micelle-like structures. Other membrane-
disruptive and non-membrane disruptive mechanisms of some AMPs are discussed in the text.
360 D.W. Hoskin, A. Ramamoorthy / Biochimica et Biophysica Acta 1778 (2008) 357–375is normally stabilized by the divalent cations like Ca2+ andMg2+
but AMPs displaces them to interact with the outer membrane.
On the other hand, mammalian cell membranes consist largely
of zwitterionic phospholipids (neutral in net charge) such as
phosphatidylethanolamine (PE), phosphatidylcholine (PC),
or sphingomyelin (SM) and are therefore less attractive to
cationic AMPs. In addition, cholesterol present in mammalian
membranes makes it harder for AMPs to disrupt lipid bi-
layer structures. Therefore, the AMPs are selectively toxic to
bacteria.
Solid-state NMR approaches have been developed and
successfully utilized to determine the secondary structure and
location of the peptide in lipid bilayers, and also to determine
the structure of the lipid bilayers. For example, solid-state NMR
studies have determined the structure and bilayer-surface
orientation of several linear AMPs including MSI-78 [32,
35–37], MSI-594 [35], magainin2 [38], MSI-843 [39], PGLa
[40–43], subtilosin A [44], KIAGAKI [45], fragments of
granulysin [46], and other peptides [47–50]. These studies
support the carpet mechanism and rule out the barrel-stave
mechanism as the mode of action for these AMPs. Thus, these
peptides have been shown to induce positive curvature strain
that leads to toroidal-type membrane disruption [24,32], which
is consistent with other biophysical studies on magainin pep-
tides. These peptides also induce significant disorder in the
hydrophobic core of lipid bilayers. On the other hand, peptideslike pardaxin [27] and alamethicin [29–31] prefer a transmem-
brane orientation and disrupt membranes via the barrel-stave
mechanism. Interestingly, pardaxin changes its orientation
depending on the membrane composition, which is consistent
with its multiple biological activities. A recent solid-state NMR
study has reported a change in the orientation of PGLa when the
concentration of the peptide was increased [41–43]. Similar
studies have also been reported for non-linear AMPs. Solid-
state NMR studies on non-helical peptides like protegrin have
revealed their mechanism of action as well [51].
While the above-mentioned mechanisms explain the bacter-
icidal activity of AMPs due to the disruption of the membrane
integrity that lead to leakage of ions and metabolites and
depolarization, there are AMPs that act on putative key intra-
cellular targets in bacteria without disrupting the cell membrane
[Hwang and Vogel, 1998]. These AMPs inhibit the synthesis of
protein or cell-wall, inhibit the activities of certain enzymes,
interfere with the metabolic processes of microbes, or interact
with DNA or RNA.
Certain AMPs have been shown to have antiviral activities:
they inhibit the replication of enveloped viruses such as
influenza A virus [52], vesicular stomatitis virus (VSV) and
human immunodeficiency virus (HIV-1) [53,54]. The generally
accepted antiviral mechanism of action is a direct interaction of
these AMPs with the envelope of the virus, leading to per-
meation of the envelope and, eventually, lysis of the virus
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above for antibacterial activity of AMPs. However, other
mechanisms for antiviral activities have also been proposed:
T22 ([(Tyr5,12, Lys7)-polyphemusin II]) a 18 amino acids
peptide analogue of polyphemusin II, an AMP isolated from the
hemocyte debris of American horseshoe crabs (Limulus
polyphemus), was found to specifically inhibit the ability of T
cell line-tropic HIV-1 to induce cell fusion [55]. On the other
hand, lactoferricin, which is an N-terminal fragment of
lactoferrin, inhibits the binding and uptake of human papilloma
virus, human cytomegalovirus, and herpes simplex virus into
human cells [56–58].
3. Membrane differences that contribute to the selectivity of
antimicrobial peptides for cancer cells
Changes in the membrane of a cell have important impli-
cations in the progression of cancer, as they play a key role in
the cell's response to its environment. The cell membrane of a
malignant tumor cell may influence its ability to grow even
without the signals that would normally inspire growth, as well
as to attach and respond to neighboring cells differently. The
cell membrane may also affect a cancer cell's motility, aiding in
invasion and metastasis. Therefore, it is important to look at the
differences between normal cells, non-malignant tumor cells,
and malignant tumor cells, as well as how these differences arise
during the progression from a normal cell to a tumor cell. These
differences likely give insight into possible treatments and
prevention. The cell membrane is a site of many such
differences, and will be further examined at the molecular level.
Fundamental differences exist between the cell membranes
of malignant cells and normal cells that likely account for the
ability of certain AMPs to kill cancer cells (hereafter referred to
as anticancer peptides; ACPs) while sparing healthy cells. In
this regard, electrostatic interactions between cationic ACPs and
anionic cell membrane components are believed to be a major
factor in the selective killing of cancer cells by ACPs. Cancer
cell membranes typically carry a net negative charge due to a
higher than normal expression of anionic molecules such as PS
(b9% of the total phospholipids of membranes) [59,60] and O-
glycosylated mucins [61,62]. In addition, the negative mem-
brane potential of cancer cells may also contribute to the selec-
tive cytotoxic activity of ACPs [63]. In contrast to neoplastic
cells, electrostatic interactions between ACPs and untrans-
formed cells are not favored because of the overall neutral
charge conferred on healthy cells by the zwitterionic nature of
their major membrane components, e.g., SM, PE, and PC [64].
Therefore, it is believed that the ACPs could kill cancer cells via
one of the aforementioned mechanisms to disrupt the cell
membrane. Another possibility is the induction of apoptosis in
cancer cells via mitochondrial membrane disruption following
ACP uptake into the cytoplasm. Other factors that contribute to
the preferential killing of cancer cells by ACPs include
membrane fluidity and cell-surface area. The membrane fluidity
of cancer cells is greater than that of untransformed cells
[65,66], which may enhance the lytic activity of ACPs by
facilitating membrane destabilization. Leuschner and Hansel[67] have suggested that cholesterol, which is a major com-
ponent of eukaryotic cell membranes [68], may protect
eukaryotic cells from the cytolytic effect of antimicrobial
peptides by altering membrane fluidity and thereby interfering
with the membrane insertion of lytic peptides. In this regard, the
rate of membrane insertion by the AMP cecropin and its
analogues is reduced when the cholesterol content of the
membrane is increased [69,70]. Interestingly, some breast and
prostate cancer cell lines have recently been shown to possess
elevated levels of cholesterol-rich lipid rafts [71], which may
make these neoplastic cells less susceptible to killing by ACPs.
Finally, cancer cells have a greater cell surface area than normal
cells due to the presence of higher numbers of microvilli
[72,73], which are minute projections of the cell membrane, that
may allow cancer cells to bind increased numbers of ACP
molecules. The microvilli are also more irregular in size and
shape, which may be due to changes in structural proteins
[73,74]. These irregularities could potentially affect receptor
accessibility, cell adhesion, and other communications between
the cancer cell and its environment, and could also play a role in
the binding of ACPs selectively to the cancer cells. Therefore,
differences in cell membrane composition, fluidity, and surface
area between cells from different types of cancer may account
for the variability in killing efficacy observed when a given
ACP is tested against different types of cancer cells [67,75].
Glycosylation of membrane-associated glycoproteins and
glycolipids undergo changes when a cell becomes cancerous,
which could play a role in determining the susceptibility of a
given cancer cell to the cytotoxic activity of ACPs. Therefore, it
would be useful to understand these important changes at the
molecular level. These changes in glycoproteins are most often
due to activation of certain glycosyltransferases, which catalyze
biosynthesis of glycoproteins. Less often, the changes can be
attributed to over-expression of glycosidases, which catalyze
degradation processes [76].
Glycosylation is the most common post-translational modi-
fication of proteins. The first main type of glycosylation is
N-linked. N-linked glycosylation occurs at the consensus se-
quence Asn–Xaa–Ser/Thr on a protein, Xaa being any amino
acid except proline. The N-linkage occurs between N-acetyl-
glucosamine (GlcNAc) and the asparagine residue; there are
various subgroups of N-glycans, but all share a common core,
the di-N-acetyl-chitobiose trimannosyl core (see Fig. 2A) [77].
The bisecting GlcNAc found in various glycoproteins
(see Fig. 2B) and the enzyme that catalyzes its attachment,
N-acetylglucosaminyltransferase III (GnT-III) may play a role
in cancer. Over-expression of GnT-III has been shown to cause
an increase in bisecting GlcNAc residues on surface glycopro-
teins or other specific proteins. This increase may affect a
number of cell processes affecting cancer progression; some
examples are: altered sensitivity to proteolysis, enhanced
adhesion properties aiding in metastasis, resistance to natural
killer cells of the immune system, impairment of signaling
pathways, and sorting of proteins [76]. It has also been reported
that cancerous cells have larger N-glycans, based on increased
β1,6GlcNAc branching of the trimannosyl core. GlcNAc-IV,
the glycosyltransferase responsible for this branching, activity is
Fig. 3. MUC1 O-glycan cores: non-cancerous (core 1 based) versus cancerous
cells (core 2 based).
Fig. 2. (A) N-glycan di-N-acetyl-chitobiose trimannosyl core; (B) bisecting GlcNAc via addition of GlcNAc by GnT-III.
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increased malignancy by altering regulation of growth and
adhesion properties [78].
The second major type of glycosylation is O-linked, which is
very common in mucins (large, heavily glycosylated proteins;
transmembrane or secreted on mucosal surfaces or in saliva).
This linkage occurs between the hemi-acetal function of N-
acetylactosamine (GalNAc) and the –OH group of a serine or
threonine residue. While composed of varying monosaccharide
units, all O-glycans are made up of 3 structural units. The core
consists of GalNAc linked to the peptide and 1 or 2 other
monosaccharides. The backbone is made of galactose (Gal) and
GalNAc sequences. Finally, the periphery (end of O-glycan) is
made up of various monosaccharides.
Changes in glycosylation of mucins in the mammary gland
are often seen in breast cancer patients; one particular mucin,
MUC1 in mammary tissue has been studied in detail. MUC1 is a
major component of luminal epithelial cells of the mammary
gland and is up-regulated during pregnancy, lactation, and in
breast cancer tissue. The extracellular portion of the transmem-
brane form of MUC1 contains 25–125 tandem repeats, which
are rich in serine and threonine residues, making them good
candidates for O-linked glycosylation [79]. In normal MUC1,
O-glycan structure is based on what is known as core 2. Core 1
consists of the GalNAc that has been added to a Ser or Thr
residue plus galactose added via a β1,3 linkage. Core 2 results
when a GlcNac is added (via β1,6 linkage) to the GalNAc of
core 1 (see Fig. 3). O-linked glycans are added sequentially as
the protein moves through the Golgi apparatus and each
addition is catalyzed by a specific glycosyltransferase. Cancer-
associated MUC1 proteins show a higher overall level ofglycosylation, have shorter glycans based on core 1 structure,
and feature a high level of sialic acid [80]. Sialic acid is a
terminal sugar and therefore is often found at the ends of the
truncated core 1 based glycans of cancer cells. This difference in
glycosylation may be due to over-expression of certain
glycosyltransferases that catalyze formation of these core 1-
based glycans. The shorter glycans also may promote higher
glycosylation along the peptide chain as it moves through
the Golgi, as they will not cause as much steric hindrance as
the larger chains would. It has also been shown that the
sequences flanking a certain Ser/Thr residue may also influence
its likelihood of being glycosylated; higher glycosylation of
nearby residues may therefore lead to even more glycosylation
[80,81].
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glycosylation occurs as a cell becomes malignant is still unclear,
such changes could play an important role in the selectivity of
ACPs. It is known that glycosylation alters the secondary
structure and dynamics of a membrane-associated peptide or
protein. Moreover, differential branching and sialic acid content
of N-linked glycans associated with transmembrane glycopro-
teins are believed to contribute to the net negative charge that is
carried by the cell membrane of many cancer cells [82].
Interestingly, glycosylation has also been shown to increase the
potency of the AMP drosocin [83]. It is therefore likely that the
binding affinity of cationic AMPs (with and without glycosyla-
tion) for cancer cells and the subsequent permeabilization of
membranes depend at least in part on altered glycosylation of
cancer cell membrane proteins. Future investigations on the
effect of ACP glycosylation on cytotoxic activity might yield
more effective anticancer compounds.
The general membrane-targeted method of cell lysis shows
potential for synergy with current cancer treatments and ACPs
have, in fact, shown additional killing of cancer cells when
tested in concert with antineoplastic drug treatments. AMPs
with cytotoxic activity against cancer cells also show potential
for overcoming common problems with multiple-drug resistant
(MDR) proteins since AMPs should not select for resistant
cancer cells. MDR proteins cause problems for current treat-
ments because they give a cancerous cell the ability to resist
treatment by simply pumping antineoplastic drugs out of the
cell where they can do no harm. An AMP, however, will kill the
cell simply by membrane disruption and avoid this resistance
mechanism. Other beneficial traits of AMPs as anticancer
agents include their wide range of activity, their ability to kill
cancer cells quickly, their ability to destroy primary tumors as
well as prevent metastasis, and the fact that they do not harm
vital organs [84].
4. α-Helical anticancer peptides
4.1. BMAP-27 and BMAP-28
BMAP-27 (amino acid sequence: GRFKRFRKKFKKLFK-
KLSPVIPLLHL) and BMAP-28 (GGLRSLGRKILRAWK-
KYGPIIVPIIRI) are bovine cathelicidin-derived AMPs with
sequences of 27 and 28 amino acid residues, respectively, that
were originally deduced from their cDNAs [85]. The cationic
NH2-terminal portion (residues 1 to 18) of these peptides is
predicted to form an amphipathic α-helix that is followed by a
hydrophobic tail (residues 19 to 27 or 28) at the COOH-
terminus. Interestingly, a truncated analogue of BMAP-28
composed of only the 18 NH2-terminal amino acid residues, as
well as a modified form of full-length BMAP-28 in which
highly hydrophobic amino acids in the COOH-terminal region
were replaced with more hydrophilic amino acids, both showed
a dramatic reduction in membrane-permeabilizing activity. This
finding indicated that the hydrophobic tail is important for
BMAP peptides to mediate their cytotoxic effect. The cytotoxic
activity of BMAP-27 and -28 against neoplastic cells was
revealed by the observation that freshly isolated human leuke-mia cells and various human leukemia cell lines exposed to
1.5–6 μM concentrations of the BMAP peptides exhibited
membrane permeabilization and an influx of Ca++, followed by
DNA fragmentation characteristic of apoptosis [86]. CEM-
CCRF human T leukemia cells with a vinblastine-resistant
phenotype were also susceptible to killing by BMAP-27 and
-28. A subsequent study demonstrated that BMAP-28 treatment
of U937 and K562 human leukemia cell lines caused a rapid
reduction in mitochondrial membrane potential in situ that was
related to a BMAP-28-induced opening of the mitochondrial
permeability transition pore, which resulted in cytochrome c
release and the initiation of cell death by apoptosis [87].
Although non-proliferating lymphocytes are not affected by the
BMAP peptides at concentrations that are cytotoxic for human
leukemia cells, at these concentrations both BMAP-27 and -28
are cytotoxic for activated human lymphocytes [86]. Low
micromolar concentrations of BMAP-27 and -28 are therefore
only active against cells that are actively proliferating. How-
ever, significant lysis of normal human neutrophils and erythro-
cytes occurs following exposure to higher concentrations
(30 μM and greater) of the BMAP peptides [85]. The relatively
narrow dosage range for BMAP-27- and BMAP-28-mediated
killing of cancer cells without deleterious hemolytic activity,
combined with the predicted inability of BMAP peptides to
effectively kill slowly proliferating or dormant neoplastic cells,
place severe restraints on the development of BMAP-27 and -28
as therapeutic anticancer agents.
4.2. Cecropin A and B
Cecropins are a class of antimicrobial peptides that were first
described in insects, including the giant silk moth Hyalophora
cecropia [88], but were later also found to be present in
mammals [89]. Cecropins derived from insect sources consist of
34–39 amino acid residues [90,91]. The best studied of these
antimicrobial peptides are cecropin A (KWKLFKKIEKV-
GQNIRDGIIKAGPAVAVVGQATQIAK) and cecropin B
(KWKVFKKIEKMGRNIRNGIVKAGPAIAVLGEAKAL),
both of which assume a secondary structure that is characterized
by the presence of two α helices [92,93]. The NH2-terminal α-
helix of cecropin A and cecropin B is highly amphipathic while
the COOH-terminal α-helix is hydrophobic. Patch-clamp
analysis of the effect of cecropin B on the Ags human stomach
carcinoma cell line revealed that peptide treatment caused short
outward currents that were consistent with the formation of
transient channel-like pores [94]. In contrast, the cecropin B3
analogue, which consists of two hydrophobic α helices, failed
to induce pore formation. Interestingly, the cecropin B1
analogue, which possesses two amphipathic α helices, shows
potent cytotoxic activity against several human leukemia cell
lines at peptide concentrations that do not lyse normal
fibroblasts or erythrocytes [95]. In fact, cecropin B1 is a more
potent cytolytic agent than cecropin B against HL-60 human
promyelocytic leukemia cells [96]. Collectively, these findings
indicate that the amphipathic NH2-terminal α-helix of cecropin
B, which is believed to interact with anionic membrane
components via its basic amino acid residues, is also able to
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hydrophobic COOH-terminal α-helix is dispensable in this
regard. Nevertheless, the hydrophobic COOH-terminal α-helix
may promote membrane insertion by the peptide, causing
positive curvature strain on the membrane that creates an ion-
permeable toroidal pore [93].
Cecropin A and B are able to lyse different types of human
cancer cells at peptide concentrations that are not harmful to
normal eukaryotic cells [91,97,98]. Cecropin B may have
potential for use in the treatment of human cancers since this
ACP exhibits in vivo antitumor activity in mice bearing ascitic
colon adenocarcinoma cells, as well as in vitro cytotoxic acti-
vity against multidrug-resistant human breast and ovarian
cancer cell lines [97]. Interestingly, the combination of cecropin
A and the conventional chemotherapeutic agents 5-fluorouracil
and cytarabine, at certain doses, shows a synergistic cytotoxic
effect on CCRF-SB human lymphoblastic leukemia cells [98].
Conventional antineoplastic drugs might therefore be used in
combination with ACPs such as cecropin A in order to lower the
dosage of the drug that is required to have a therapeutic effect
and thereby reduce chemotherapy-induced side effects. How-
ever, therapeutic use of cecropins or other ACPs will require
repeated administration in order to maintain systemic levels of
the peptide that are equivalent to the high concentrations
required for ACPs to kill human cancer cells in culture or in
mice. One attractive alternative is to transfer genes encoding
ACPs directly into cancer cells or to the vicinity of solid tumors.
In this regard, the introduction of expression constructs
containing the cecropin A gene into EJ human bladder carci-
noma cells prevented or reduced the growth of the tumor cells in
immune-deficient mice [99]. Gene therapy using ACPs such as
cecropin A may therefore 1 day be possible for the treatment of
human cancers.
4.3. LL-37/hCAP-18
LL-37/hCAP-18 (human cationic AMP of 18 kDa) is the
only human cathelicidin-derived AMP that has been identified
to date [100]. This cathelicidin is initially synthesized as a
preproprotein (hCAP-18) that is subsequently processed to its
active form (LL-37) by proteinase 3-mediated extracellular
cleavage [101]. hCAP-18 is expressed in a variety of cell types,
including neutrophils [102] and squamous epithelial cells [103].
LL-37 (LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLV-
PRTES) is a 4.5 kDa AMP that has antimicrobial activity at
low micromolar concentrations against a variety of Gram-
positive and Gram-negative bacteria. Unlike other AMPs,
LL-37 is toxic to eukaryotic cells at a slightly higher con-
centration (25–30 mM, which is 3–5 times its MIC value).
LL-37 has been found to have additional defensive roles such as
regulating the inflammatory response and chemo-attracting
cells of the adaptive immune system to wound or infections
sites, stimulation of angiogenesis and chemotaxis of neutro-
phils, monocytes and T-cells. This peptide is found throughout
the body: in epithelial cells of testis, respiratory tract and
gastrointestinal, in leukocytes and in skin. In addition, LL-37
has been expressed in Escherichia coli and purified forbiophysical studies [104]. CD and NMR studies have shown
that LL-37 is unstructured in pure water but forms helical
oligomers in solution either at a higher peptide concentration or
in the presence of ions [105]. This property of the peptide is
believed to be important as the oligomer can escape the
proteolytic degradation [106]. Solid-state NMR studies have
shown that LL-37 also assumes an α-helical conformation in a
membrane environment and its oligomeric nature depends on
the membrane composition. These studies revealed that the α-
helical structure is comprised of both cationic and hydrophobic
faces that orient in a parallel manner with lipid membranes,
suggesting a carpet-like rather than channel-forming mechan-
ism of cytotoxicity [105]. In addition, solid-state NMR and
DSC experiments have shown that LL-37 is highly sensitive to
the membrane composition, upon binding to membranes
changes the head group conformation of phospholipids, induces
positive curvature strain on lipid bilayers, and significantly
disorders the hydrophobic core of the membrane [107]. More
details on the structural and functional properties of this
intriguing molecule can be found in a recent review article
[20,21].
A COOH-terminal fragment of hCAP-18 consisting of
amino acid residues 109–135 (hCAP18109–135), which corre-
sponds to amino acid residues 6–32 of LL-37, was recently
found to induce apoptosis in a human oral squamous carcinoma
cell line via a mechanism involving mitochondrial depolariza-
tion without any detectable activation of caspase-3 [108]. This
finding is in line with a report that the core cytotoxic activity
of LL-37 resides within a 13 amino acid residue fragment of
the COOH-terminal region corresponding to amino acid
residues 17–29, designated LL-37(17–29) [109]. Although
LL-37(17–29) is equally cytotoxic to drug-sensitive and drug-
resistant variants of the KB human squamous cancer cell line,
LL-37(17–29) also kills untransformed human endothelial
cells. Native LL-37 is similarly cytotoxic to human peripheral
blood lymphocytes [110] and has significant hemolytic activity
[106]. LL-37(17–29) and native LL-37 therefore lack the
selectivity for cancer cells required of an ACP. In contrast, a
tumoricidal concentration of hCAP18109–135 did not have any
cytotoxic effect on either human gingival fibroblasts or the
HaCaT human keratinocyte cell line [108]. The apparent se-
lective cytotoxic activity of hCAP18109–135 against human
cancer cells indicates that hCAP18109–135 warrants further
investigation as a potential therapeutic ACP.
4.4. Magainins and other amphibian-derived anticancer
peptides
The skin secretions of amphibians are a rich source of AMPs,
several of which (aurein 1.2, citropin 1.1, gaegurins, magainins
and analog peptides of magainins) have been reported to be
selectively cytotoxic for human cancer cells [111–116]. The
best studied of these ACPs are the magainins, which are AMPs
isolated from the skin of the African clawed frog Xenopus
laevis [117]. Magainins are comprised of 21 to 27 amino acid
residues that create an α-helical secondary structure character-
ized by separate cationic and hydrophobic faces. Magainin 2
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synthetic analogues (magainins A, B, and G) cause the rapid
lysis of both hematopoietic and solid tumor cell lines at con-
centrations that are 5–10 fold lower than magainin concentra-
tions that are lytic for normal human peripheral blood
lymphocytes or neutrophils [115,118]. Magainin 2 also shows
selective cytotoxic activity against several human bladder cell
lines with an average IC50 of approximately 200 μM [119].
Fluorescence spectrophotometric measurement of cancer cell
membrane potential following exposure to magainin 2 or syn-
thetic magainin analogues indicates that magainins lyse tumor
cells by forming ion-conducting α-helical channels in the
cancer cell membrane [115]. However, there is some evidence
that, at lower concentrations, magainins destabilize the mem-
brane bilayer via the carpet model [120]. A more recent study
shows that a magainin 2 derivative is able to permeabilize and
cross the cell membrane of HeLa human cervical carcinoma
cells via an energy- and receptor-independent mechanism [121].
Magainins that gain access to the cytosolic compartment of
cancer cells may trigger the mitochondrial pathway of apoptosis
since magainins have been shown to form channels in the
membranes of isolated rat liver mitochondria [122]. Interest-
ingly, 10–50 nM concentrations of magainin 1 have recently
been shown to induce apoptosis in HL-60 human promyelocytic
leukemia cells via a mechanism that involves cytochrome c
release from mitochondria and an increase in proteosome
activity [116]. At the present time it is not clear whether
magainins kill human cancer cells primarily through membrane
lysis and/or apoptosis. A large number of recent biophysical
studies focused on the mechanism of membrane-disruption by
magainins (e.g., magainin 2 [38], PGLa [40–43], MSI-78
(commercially known as pexiganan) [32,35,36], MSI-594 [35],
MSI-843 [39] and other synthetic variants) on model mem-
branes. These peptides are unstructured in solution, form a α-
helical structure in membranes, bind to the membrane with the
helical axis parallel to the membrane surface and with a high
affinity for negatively charged membranes, form oligomers,
induce positive curvature strain, and disrupt membranes via
carpet-toroidal-pore mechanism, which lead to fragmentation of
membranes into bicelles and micelles after a sufficient time
(N1 month). Some of these peptides like magainin2 [123],
PGLa [43] and MSI-78 [35,36] form antiparallel α-helical
dimers in membranes.
A number of synthetic magainin analogues exhibit superior
cytotoxic activity against neoplastic cells in comparison to
native magainins [115,124–126]. Superior selectivity for
human cancer cells is exhibited by magainin G whereas
magainin B is the most potent of the synthetic magainin
analogues in terms of cytotoxicity [115]. Magainins A and G,
which were designed to have increased α-helical potential and
decreased hemolytic activity in comparison to native magainin
1 and 2, inhibit the growth of human small cell lung cancer cell
lines, including drug-resistant tumor cell variants, with an
average IC50 of approximately 9 μM [124]. In contrast, twice
the concentration of magainin A or G is needed to inhibit the
growth of normal human fibroblast cell lines. Magainin A and G
also enhance the effectiveness of the chemotherapeutic agentsDDP and VP-16, suggesting that these synthetic magainin
analogues might be used in combination with conventional
anticancer drugs in order to reduce chemotherapy-induced side
effects. Two additional synthetic magainin analogues (MSI-
136, comprised of L-amino acids and MSI-238, comprised of D-
amino acids) designed to have an enhanced amphipathic α-
helical structure, were found to have superior in vitro cytotoxic
activity against human lung carcinoma cells in comparison to
native magainin 2 and to increase survival of ovarian teratoma-
bearing mice [125]. All-D-amino acid MSI-238 was more
effective in vivo than all L-amino acid MSI-136 or magainin 2,
most likely because of decreased susceptibility to proteolytic
degradation. An additional synthetic all-D-amino acid magainin
analogue designated MSI-511 showed selective killing human
melanoma cells in vitro at concentrations that do not harm
normal melanocytes [126]. Moreover, intratumoral injection of
MSI-511 completely eradicated human melanoma cells grown
as subcutaneous xenografts in immune-deficient mice, provid-
ing evidence that locoregional therapy with protease-resistant
magainin peptides may be useful for the treatment of malignant
melanoma in humans.
Gaegurins are a class of six related AMPs that have been
isolated from the skin of a Korean frog Rana rugosa [127]. The
gaegurins assume a random-coil conformation in aqueous
solution but adopt an amphipathic α-helical structure in mem-
brane environments, allowing these AMPs to mediate cytolysis
by the barrel stave and/or carpet mechanism [128]. More recent
studies have revealed that gaegurin 5 (FLGALFKVASKVLPS-
VKCAITKKC) and gaegurin 6 (FLPLLAGLAANFLPTIICFI-
SYKC) have selective cytotoxic activity against neoplastic cells
[113,114]. Gaegurin 5 and 6 are each comprised of 24 amino
acid residues. Gaegurin 5 and two synthetic peptide analogues
are able to selectively kill a range of human tumor cell types,
including HCT116 colon and MCF-7 breast carcinoma cells,
while showing only minimal hemolytic activity [113]. Gaegurin
6 and a synthetic peptide analogue (PTP7) have a similar broad
spectrum of cytotoxic activity against human cancer cells with
no detectable cytotoxicity against peripheral blood mono-
nuclear cells and minimal hemolytic activity [114]. In addition,
gaegurin 6 and PTP7 are active against a multidrug-resistant
variant of the MCF-7 breast cancer cell line. Gaegurin 6- and
PTP7-mediated cytotoxicity may involve apoptosis since DNA
fragmentation was detected in MCF-7 breast cancer cells that
were exposed to these ACPs.
Aurein 1.2 (GLFDIIKKIAESF) is a small cationic AMP
comprised of 13 amino acid residues that has been isolated from
the Australian bell frog Litoria raniformis [111]. NMR studies
indicate that aurein 1.2 adopts an α-helical structure in solution.
Aurein 1.2 is moderately cytotoxic for 57 of 60 human tumor
cell lines but does not lyse erythrocytes at concentrations as
high as 100 μg/ml, which is sufficient to kill most human cancer
cells. Citropin 1.1 (GLFDVIKKVASVIGGL) is a relatively
small AMP isolated from the tree frog Litoria citropa. This
AMP is able to kill a wide range of human hematopoietic and
non-hematopoietic tumor cell lines at concentrations that do not
cause significant lysis of red blood cells [112]. Citropin 1.1,
which is comprised of 16 amino acid residues, has an α-helical
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philic regions. The relatively small size of aurein 1.2 and
citropin 1.1 implies that these ACPs mediate their cytotoxic
effect via the carpet mechanism since ACPs need to be
comprised of at least 20 amino acid residues in order to span
eukaryotic cell membranes and cause cytolysis by the barrel-
stave mechanism [129,130]. However, it is important to note
that peptides comprised of fewer than 20 amino acid residues
may dimerize end-on in order to effect complete penetration of
biological membranes [131].
4.5. Melittin
Melittin (GIGAVLKVLTTGLPALISWIKRKRQQ), an alka-
line polypeptide comprised of 26 amino acid residues, is the
major component of European honeybee (Apis mellifera)
venom [132]. The NH2-terminal region of melittin is largely
hydrophobic whereas the region at the COOH-terminus
contains positively-charged amino acid residues and is hydro-
philic [133]. Melittin forms channels in lipid bilayers [134,135]
and is lytic for both cancer cells and normal, healthy cells,
including erythrocytes [133,135,136]. Nevertheless, murine
L1210 leukemia cells have been reported to be several-fold
more sensitive to melittin-mediated cytotoxicity than are normal
mouse splenocytes or bone-marrow cells [137]. At low mem-
brane concentrations, melittin assumes an α-helical structure
that lies parallel to the bilayer plane [138]. However, recent
studies indicate that monomeric melittin has little effect on a
membrane mimetic bilayer structure whereas a dimeric form of
melittin causes destabilization of membrane mimetic bilayers
formed from dioleoylphosphatidylcholine [139]. Self associa-
tion of amphipathic α-helical monomers of melittin is therefore
suggested to be responsible for the large perturbations in
membrane integrity that result in cellular lysis. Melittin is
believed to cause damage to cell membranes via the barrel-stave
mechanism [140]. However, melittin has additional effects on
cancer cells. Melittin counter-selects for ras-over expressing
cancer cells through a mechanism that involves the hyper-
activation of phospholipase A2, an influx of Ca
++, and the
subsequent destruction of the transformed cells [141,142].
Furthermore, melittin-mediated cytolysis of U937 human
monocytic leukemia cells is associated with the transient
activation of endogenous phospholipase D, which has been
suggested to participate in an uncharacterized signal transduc-
tion pathway involved in the permeabilization of cancer cell
membranes by this ACP [143].
Because of the relative lack of selectivity displayed by
melittin for cancer cells, efforts have been focused on targeting
melittin to neoplastic cells and/or tumor vasculature. One
strategy is based on the use of matrix metalloproteinase-2,
which is over expressed by human cancer cells and tumor-
associated endothelium [144], to selectively cleave a melittin–
avidin conjugate, thereby restoring the lytic function of melittin
at the site of matrix metalloprotease-2 expression [145]. DU 145
prostate carcinoma cells and SKOV3 ovarian carcinoma cells
that exhibit high levels of matrix metalloproteinase-2 activity
are killed by the melittin–avidin conjugate whereas normalmouse L-cell fibroblasts that possess little matrix metallopro-
tease-2 activity are unaffected by the melittin–avidin conjugate.
In addition, intratumoral administration of the melittin–avidin
conjugate causes a significant reduction in the growth of B16
murine melanoma cells in syngeneic mice. Alternatively, tumor-
specific antibodies can be used to target melittin to tumor cells.
In this regard, administration of an immunoconjugate contain-
ing a melittin-like peptide improved the survival of immune-
deficient mice bearing subcutaneous human prostate carcinoma
xenografts [146]. Melittin-based gene therapy of human cancers
is also a possibility, as demonstrated by the adenovirus-
mediated transfer of the melittin gene under the control of the
α-fetoprotein promoter to BEL-7402 human hepatocellular
carcinoma cells, which resulted in a dramatic inhibition of the in
vitro and in vivo (in immune-deficient mice) growth of the
hepatocellular carcinoma cells [147]. Intratumoral injection of
the adenovirus–melittin construct also caused subcutaneous
BEL-7402 tumors in immune-deficient mice to shrink and
eventually disappear. Clearly, the targeted delivery of melittin
and other ACPs to tumor sites has exciting possibilities as a
therapeutic approach.
5. β-sheet anticancer peptides
5.1. Defensins
Defensins are a group of closely-related, Cys–Arg-rich,
cationic AMPs comprised of 29 to 45 amino acid residues [148].
The six conserved Cys residues that are a characteristic feature
of defensins form three intramolecular disulfide bridges
between the NH2-terminal and COOH-terminal regions of the
peptide, creating a cyclic, triple-stranded, amphiphilic β-sheet
structure, making up the characteristic “defensin-like” fold and
spatially separated hydrophobic and hydrophilic regions
[149,150]. Although defensins have been isolated from many
different species, α- and β-defensins of human origin remain
the best studied [10,22,151]. The disulfide connectivities in
α-defensins are Cys1–Cys6, Cys2–Cys4 and Cys3–Cys5 (the
number indicates the location of the Cys residue in the amino
acid sequence from the N-terminus), while in β-defensin are
Cys1–Cys5, Cys2–Cys4 and Cys3–Cys6.
Human neutrophil peptides (HNPs)-1 (ACYCRIPACIA-
GERRYGTCIYQGRLWAFCC), HNP-2 (CYCRIPACIAGE-
RRYGTCIYQGRLWAFCC), and HNP-3 (DCYCRIPACI-
AGERRYGTCIYQGRLWAFCC) are α-defensins that were
originally purified from the azurophilic granules of neutrophils
[152] and were later found to have a cytotoxic effect on several
different types of human and mouse tumor cells, including Raji
human B-lymphoma cells, human oral squamous carcinoma
cells, and MOTmouse teratocarcinoma cells [153–155]. Higher
concentrations (N25 μg/ml) of HNP-1, -2, and -3 suppress DNA
synthesis in renal cell carcinoma lines, as well as reducing
cancer cell viability [156]. Rabbit macrophage-associated
defensins that are homologues of HNP-1 and -2 are also able
to lyse murine tumor cells [157]. Tumor cell killing by HNP-1,
-2, and -3 involves a membrane binding event, most likely
mediated by electrostatic interactions, followed by rapid col-
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[154,158]. Membrane permeabilization by HNPs has been
attributed to the channel-forming ability of these peptides
because HNP-1 has been shown to form voltage-dependent,
ion-permeable channels in planar phospholipid bilayer mem-
branes [159]. HNP-mediated cytotoxicity may also involve
DNA damage since single strand DNA breaks were detected in
HNP-treated target cells, although nucleosome-sized fragments
of DNA that are characteristic of apoptosis were not observed
[160]. In addition to their cytotoxic activity, HNP-1 and -3 may
be able to interfere with neovascularization during tumor
development because these α-defensins inhibit the α5β1
integrin-dependent migration and adhesion of endothelial cells
to fibronectin in response to vascular endothelial growth factor
(VEGF) [161]. In addition, HNP-1 and -3 inhibited VEGF-
induced proliferation of endothelial cells via the induction
of apoptosis. Unfortunately, the clinical utility of human α-
defensins is limited by the fact that HNPs are not tumor-
selective, causing the lysis of normal human leukocytes,
epithelial cells, and fibroblasts [153,162]. In addition, serum
strongly inhibits HNP-mediated cytotoxicity [154], which poses
an obstacle to the systemic administration of these human
α-defensins.
5.2. Lactoferricin
Lactoferricin is a cationic AMP produced by acid-pepsin
hydrolysis of mammalian lactoferrin [163], an iron-binding
protein that is present in the secretory granules of neutrophils
and in secreted fluids that include milk and saliva [164–166].
Bovine lactoferricin (LfcinB) isolated from cow's milk consists
of 25 amino acid residues (FKCRRWQWRMKKLGAP-
SITCVRRAF), including two Cys residues that create a
disulfide bond linking the highly positively-charged NH2-
terminal region and the COOH-terminal region of the peptide
[167]. In aqueous solution, LfcinB assumes a twisted β-sheet
configuration with the basic amino acid residues arranged on
one face and most of the hydrophobic amino acid residues
arranged on the other face [168]. LfcinB exhibits in vitro
cytotoxic activity against many different types of mouse and
human cancer cell lines, including leukemia cells, fibrosarcoma
cells, various carcinomas, and neuroblastoma cells [169–172],
at concentrations that do not substantially affect the viability of
normal fibroblasts, lymphocytes, epithelial cells, endothelial
cells, or erythrocytes [171,173]. The cytotoxic activity of
LfcinB against cancer cells is very much dependent on the
amphipathic structure and high net positive charge of the
peptide since cytotoxic activity is increased in LfcinB deriva-
tives with clear cationic and hydrophobic sectors, while a
glutamic acid-containing homologue of murine lactoferricin
lacks the ability to kill cancer cells [174–176]. LfcinB binds to
cancer cell membranes, causing membrane integrity to be lost
due to the formation of transmembrane pores that allow the
peptide to enter the cytoplasmic compartment of the cancer
cell and co-localize with negatively-charged mitochondria
[172,177]. Although mouse fibrosarcoma cells and human
neuroblastoma cells exposed to LfcinB die primarily vianecrosis caused by a cell membrane lytic effect [172], LfcinB
kills human leukemia and breast carcinoma cells by a process
that involves the sequential generation of reactive oxygen
species, loss of mitochondrial transmembrane potential, and
activation of the caspase cascade culminating in cell death by
apoptosis [171,178]. Whether LfcinB-treated cancer cells die by
necrosis or apoptosis may ultimately be determined by the
degree of irreparable LfcinB-mediated damage to the cytoplas-
mic membrane relative to mitochondrial membrane damage
caused by internalized LfcinB. Although the cytotoxic activity
of LfcinB is reduced in the presence of high concentrations of
serum [178], systemic or intratumoral administration of LfcinB
is nonetheless able to inhibit the in vivo growth and/or meta-
stasis of several different tumor types in mice [170,172,178].
Recently, LfcinB has been shown to suppress both basic
fibroblast growth factor (bFGF)- and VEGF-driven prolifera-
tion and migration of human endothelial cells in vitro, as well as
interfering with bFGF- and VEGF-induced angiogenesis in
subcutaneous Matrigel plugs implanted in mice, by competing
with bFGF and VEGF for growth factor receptor-associated
heparan sulfate proteoglycans on the endothelial cell surface
[179]. The antiangiogenic activity of LfcinB is dependent on the
primary structure of the peptide since a scrambled peptide
comprised of the same amino acid residues failed to effectively
compete with bFGF or VEGF for heparin-like binding sites on
endothelial cells. These findings are consistent with an earlier
report that subcutaneous administration of LfcinB inhibited
blood vessel development in B16–BL6 melanoma tumors im-
planted in syngeneic mice [178]. However, the relative
contributions of the cytotoxic and antiangiogenic effects of
LfcinB to the inhibition of tumor progression in vivo are not
known at the present time.
5.3. Tachyplesin I
Hemocytes of the horseshoe crab (Tachypleus tridentatus)
are the source of the cationic AMP tachyplesin I [180], which
consists of 17 amino acid residues (KWCFRVCYRGI-
CYRRCR) arranged in two anti-parallel β-sheets that are held
in place by two disulfide bonds [181]. This configuration allows
all six of the basic amino acid residues (Arg, Lys) of tachyplesin
I to be exposed on the surface of the peptide, resulting in an
amphipathic structure. While it is believed that a disulfide bond
provides stability to the structure and also against proteolytic
degradation, a recent showed that tachyplesin I without Cys
residues retained the antimicrobial activity of the wild-type
peptide, but may not be stable in serum [182]. Tachyplesin I has
a unique method of killing cancer cells. In a recent study,
tachyplesin I was shown to bind to hyaluronan on hyaluronan-
over expressing human TSU prostate carcinoma cells, as well as
to the C1q component of complement in human serum, leading
to activation of the classical complement pathway and
complement-mediated lysis of tachyplesin I-coated cancer
cells [183]. The C1q-binding activity of tachyplesin I was
dependent on the secondary structure of the peptide since
denatured tachyplesin I bound significantly less C1q. Inter-
actions between tachyplesin I and hyaluronan are believed to
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because many tumor cells tend to express hyaluronan at levels
that are much higher than those found on normal tissues [184].
Hyaluronan is also present in large amounts on the surface of
endothelial cells involved in neovascularization [185], such as
occurs during tumor development, suggesting that tachyplesin I
might cause complement-mediated destruction of tumor-
associated vasculature, as well as neoplastic cells. Interestingly,
heat-inactivation of serum complement only partially protected
tachyplesin I-treated TSU prostate cancer cells from lysis,
suggesting that tachyplesin I has additional effects on cancer
cells that can lead to cell death. In this regard, RGD-targeting of
synthetic tachyplesin I to integrins on the surface of TSU
prostate cancer cells and endothelial cells in vitro results in the
inhibition of cell growth due to cell membrane damage and the
induction of caspase-dependent apoptosis [186]. Administration
of RGD-tachyplesin I also inhibits the in vivo growth of B16
melanoma cells in mice. It is possible that the overall positive
charge of tachyplesin I allows internalized RGD-tachyplesin I to
target and disrupt negatively-charged mitochondrial membranes
in the cancer cells, thereby triggering the intrinsic pathway of
apoptosis. However, at the present time it is not clear whether
the hyaluronan-binding activity of tachyplesin I contributes to
the cytotoxic effect of RGD-tachyplesin I on cancer cells.
Although RGD-tachyplesin I-treated mice did not experience
any obvious side-effects, it is important to note that, at higher
concentrations, tachyplesin I interacts with neutral lipids in the
plasma membrane of erythrocytes, resulting in membrane
permeabilization and hemolysis [187].
Tachyplesin I also inhibits the growth of cancer cells through
a non-cytolytic mechanism. Tachyplesin I treatment of SMMC-
7721 human hepatoma cell and BGC-823 human gastric adeno-
carcinoma cell cultures leads to a decrease in the proliferative
capacity of these cancer cells [188,189]. Reduced growth of
SMMC-7721 cells in the presence of tachyplesin I was
associated with the reversal of malignant morphological and
ultrastructural features, decreased expression of tumor-asso-
ciated antigens (α-fetoprotein, proliferating cell nuclear anti-
gen), modulation of differentiation-associated enzyme (γ-
glutamyltransferase, tyrosine aminotransferase) expression,
decreased expression of the c-myc oncogene, and increased
expression of the tumor suppressor gene p21WAF1/CIP1 [188].
Tachyplesin I treatment of BGC-823 cells also altered the
morphology and ultrastructure of these cancer cells [190], as
well as inhibiting their in vitro proliferation, decreasing c-myc,
c-erbB-2 and mtp53 oncogene expression, and increasing p16
tumor suppressor gene expression [189]. Taken together, these
findings indicate that tachyplesin I is capable of inducing tumor
cell differentiation, thereby reversing the malignant phenotype.
6. Linear anticancer peptides
PR-39 is a Pro–Arg-rich member of the cathelicidin family
that was originally isolated from porcine small intestine [191]
and, later, from porcine neutrophils [192]. This linear AMP is
comprised of 39 amino acid residues (RRRPRPPYLPRPRP-
PPFFPPRLPPRIPPGFPPRFPPRFP) and lacks the secondarystructure that is characteristic of other ACPs. The mechanism by
which PR-39 exerts anticancer activity is also unique among
ACPs. Treatment of human hepatocellular carcinoma cell lines
with PR-39 results in the induction of syndecan-1 expression
[193]. Similar results were obtained when HLF hepatocellular
carcinoma cells were transfected with the PR-39 gene. PR-39
might therefore be able to prevent or reduce the invasion and
metastasis of tumor cells because heightened syndecan-1
expression by human myeloma and hepatocellular carcinoma
cells has been associated with a reduction in the invasive
activity of these cancer cells [193,194]. Suppressed motile
activity and altered actin structure in PR-39-transfected
hepatocellular carcinoma cells might also contribute to the
PR-39-mediated inhibition of cancer cell invasion [193]. In
addition, ras-transformed cells transfected with the PR-39 gene
were suppressed in their ability to proliferate both in vitro and
in vivo [195].
PR-39 binds to eukaryotic cells in a receptor-dependent
manner and subsequently rapidly gains access to the cytosolic
compartment, without permeabilizing the plasma membrane
[196]. Once inside the cell, SH3-binding motifs allow PR-39 to
complex with multiple SH3-containing cytoplasmic proteins,
including the signaling adaptor protein p130Cas and the p85α
regulatory subunit of phosphatidylinositol 3-kinase [195,196].
Recent studies on variants of the PR-39 peptide have shown that
the SH3-binding and syndecan induction activities of PR-39 are
dependent on the presence of NH2-terminal arginine residues
[197]. The anticancer activity of PR-39 is most likely a
consequence of the peptide interacting with and affecting
the activity of SH3-bearing proteins that are involved in key
cellular signaling processes. For example, endothelial cells
treated with PR-39 show altered localization of p130Cas while
phosphatidylinositol 3-kinase activity in ras-transformed
NIH3T3 cells is suppressed as a consequence of PR-39 binding
to p85α [195,197].
7. Hybrid and Synthetic Anticancer Peptides
7.1. Cecropin A-based Hybrid Anticancer Peptides
In recent years, a number of attempts have been made to
improve upon naturally occurring ACPs by creating hybrid
ACPs that incorporate the best qualities of individual ACPs.
Research on hybrid ACPs has been largely focused on com-
bining the NH2-terminal positively-charged α-helical region of
cecropin Awith the NH2-terminal α-helical hydrophobic region
of either melittin (CA-ME) or magainin 2 (CA-MA) [198–200].
Both CA(1–8)–ME(1–12) and CA(1–8)–MA(1–12) exhibit
cytolytic activity against human small cell lung cancer cell lines,
although at the highest peptide concentrations CA(1–8)–ME
(1–12) has modest hemolytic activity whereas CA(1–8)–MA
(1–12) has little or no lytic effect on erythrocytes [198]. Studies
on CA(1–8)–ME(1–12) and CA(1–8)–MA(1–12) analogues
containing amino acid substitutions suggested that flexibility
in the hinge region of these hybrid peptides is an important
factor in their cytolytic activity [199]. In this regard, a com-
parison between the three-dimensional structures of CA(1–8)–
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hinge region (Gly–Ile–Gly) dictates whether these hybrid
peptides have sufficient conformational flexibility to allow their
cationic NH2-terminal α-helix to interact with and align in a
parallel fashion with the cell membrane whilst their hydro-
phobic COOH-terminal α-helix inserts into and spans the cell
membrane, thereby triggering cytolysis [200]. Thus, omission
of the Gly–Ile–Gly hinge region resulted in a dramatic re-
duction in the anticancer and hemolytic activity of CA(1–8)–
ME(1–12) and CA(1–8)–MA(1–12). The α-helical content and
amphipathic properties of these hybrid peptides were also found
to be important determinants of hemolytic activity since, in
comparison to CA(1–8)–MA(1–12), hemolysis-inducing CA
(1–8)–ME(1–12) has a longer and more stable α-helix and is a
more hydrophobic molecule. P18 is an α-helical ACP that was
designed from CA(1–8)–MA(1–12) [201]. This hybrid ACP is
selectively cytotoxic for human cancer cells, including Jurkat T
leukemia cells, K562 chronic myeloid leukemia cells, and
MDA-MB-361 breast carcinoma cells, without causing any
hemolysis. Structure–function analysis showed that the COOH-
terminal α-helical region of P18 is important for cytolytic
activity against human cancer cells whereas the NH2-terminal
α-helical region is not. The design of hybrid ACPs such as P18
and its analogues that exert potent cytotoxic activity against
neoplastic cells without any appreciable hemolytic activity or
cytotoxicity against healthy cells represents an important
advance in the quest for new anticancer agents.
7.2. Diastereomeric and other synthetic anticancer peptides
Synthetic diastereomeric lytic peptides are of considerable
interest as ACPs because of their ability to selectively perme-
abilize negatively-charged phospholipid membranes, including
those of cancer cells, while resisting enzymatic degradation by
serum proteins [202,203]. D-K4R2L9 is a diastereomeric
amphipathic peptide comprised of Leu, Lys and Arg residues,
totaling 15 amino acid residues, with one third of its sequence
comprised of D-amino acids [204]. The D-K4R2L9 peptide binds
to and lyses B16-F10 mouse melanoma cells in culture at
concentrations that do not harm normal 3T3 fibroblasts or
erythrocytes. Moreover, intravenous administration of D-
K4R2L9 was effective in preventing intravenous-injectedFig. 4. Reduction of tumor size by a synthetic anticancer peptide, D-K6L9:maD122 lung carcinoma cells from forming lung tumors in
mice. A subsequent study revealed that it is possible to obtain
similar selective in vitro cytotoxic activity against human
prostate cancer cell lines using a modified 15-amino acid
diastereomeric amphipathic peptide designated D-K6L9, which
contains D-Lys and D-Leu residues in one third of its sequence
[205]. Interestingly, an analogue of the D-K6L9 peptide that is
composed entirely of L-amino acids (L-K6L9) had similar
anticancer activity but was also lytic for normal fibroblast and
erythrocytes. This highlights another important advantage of
employing D-amino acids in the construction of synthetic ACPs.
In addition, the D-K6L9 peptide showed synergistic cytotoxic
activity with the conventional anticancer drug doxorubicin
against both androgen-dependent and androgen-independent
prostate cancer cells. Importantly, intratumoral injections of D-
K6L9 caused 22RV1 prostate carcinoma xenografts in immune-
deficient mice to decrease in size and, in some cases, completely
disappear. In contrast, L-K6L9 lacked in vivo antitumor activity
due to its complete inactivation by serum proteins. Recently,
systemic administration of D-K6L9 was shown to inhibit the
growth and metastatic spread of 22RV1 prostate carcinoma cells
and MB-231 breast carcinoma cells in immune-deficient mice,
as shown in Fig. 4 [206]. The selective cytotoxicity of D-K6L9
for human cancer cells was due to the binding of cationic
D-K6L9 to anionic surface-exposed PS, followed by cyto-
plasmic membrane depolarization and necrosis.
Targeting or membrane-penetrating sequences have also
been used to enhance the selectivity or activity, respectively, of
synthetic ACPs. Targeting domains (cyclic CNGRC or double-
cyclic RGD-4C) have been coupled to the pro-apoptotic peptide
(KLAKLAK)2, which is comprised of 14 D-amino acid residues
and kills by disrupting mitochondrial membranes following its
uptake into the cytosolic compartment [207]. These targeted
synthetic peptides were selectively cytotoxic for endothelial
cells under angiogenic conditions, i.e. tumor vasculature, but
did not harm endothelial cells under angiostatic conditions. As a
result, systemic administration of targeted (KLAKLAK)2
peptides significantly prolonged the survival of immune-
deficient mice bearing human breast carcinoma xenografts, as
well as dramatically reducing tumor volume without any
apparent treatment-related toxicity. In another approach, the
(KLAKLAK)2 peptide has been fused to the PTD-5 proteinle mice without (left) and with treatment using the peptide (right) [206].
370 D.W. Hoskin, A. Ramamoorthy / Biochimica et Biophysica Acta 1778 (2008) 357–375transduction domain in order to promote rapid internalization of
the peptide [208]. The DP-1 peptide created in this way triggers
apoptosis in cultures of mouse fibrosarcoma cells and human
head and neck tumor isolates. Moreover, intratumoral injections
of DP-1 caused established MCA205 mouse fibrosarcoma
tumors to regress and, in some cases, totally disappear without
any apparent side effects. In a similar approach, a cell-pene-
trating domain consisting of seven D-arginine residues (r7) was
coupled to the D-amino acid configuration synthetic mitochon-
drial membrane-disrupting peptide kla [209]. In vitro treatment
with r7-kla resulted in rapid peptide uptake and the induction of
apoptosis in different types of human cancer cells, including
breast, colorectal, and prostate carcinoma cell lines. In addition,
a single intratumoral injection of r7-kla triggered apoptosis,
along with significant tumor tissue loss and extensive necrosis,
in HT1080 human fibrosarcoma xenografts grown in immune-
deficient mice. However, it is important to note that synthetic
ACPs such as DP-1 and r7-kla that have been engineered for
rapid cellular uptake will also need to be selectively targeted to
tumor cells in order to avoid unacceptable toxicity following
systemic administration.
8. Summary and outlook
Current cancer treatments have many harmful side effects,
since commonly used antineoplastic drugs target all rapidly
dividing cells, rather than solely cancerous cells. In contrast,
certain AMPs seem to show specificity towards malignant cells.
It is clear that a great deal of further study must be devoted to
studying the exact mechanism of interaction of ACPs with
cancer cells and which of the characteristics of a cancer cell
make some AMPs preferentially target them. In particular,
biophysical studies dealing with the structure, dynamics,
topology, mechanism of membrane disruption, and the role of
individual components of membranes using a variety of model
membranes mimicking cancer and normal cells would provide
insights into the function of an ACP at a very high-resolution.
For example, recently developed solid-state NMR approaches
and model membranes to mimick various types of cell
membranes [20] can be utilized to solve the high-resolution
structure and oritentation of ACPs and also possible interaction
with glycosylated proteins. Since NMR structures of most of
ACPs are known, it would be relatively easy to interpret the
experimental data that lead to membrane disruption by ACPs. It
would also be worthwhile to design glycosylated ACPs to
determine if glycosylation increases their potency. In addition,
cross-linking and/or the use of fluorinated-amino acids to
increase the stability of oligomeric structures as recently shown
for MSI-78 could be useful. Such studies would greatly
facilitate the design of more potent and highly selective ACPs
with a variety of modes of action against human cancer cells, as
well as notable advantages over current drug-based cancer
treatments.
Also, current anticancer drugs must be taken into the cell in
order to be effective, which makes it possible for cancer cells
develop resistance to these drugs by pumping them out of the
cell. Again, ACPsmay have an advantage here, as they act on thecell membrane without having to be taken into the cancer cell.
Major requirements for clinical usage of ACPs in cancer
treatment include a very high specificity (low cytolytic activity
to normal mammalian cells and red blood cells) and killing
ability, as well as stability in serum. Serum has often been shown
to affect the potency of AMPs, including ACPs; for example,
LDL (low density lipoprotein), a type of cholesterol, is a strong
inhibitor of peptide-mediated cell lysis. However, certain
naturally occurring ACPs are more stable in serum. Synthetic
ACPs have been specifically designed for this purpose as well.
In this regard, recent studies have shown that ACPs containing
D-amino-acids are more stable against proteolytic degradation.
ACPs that are foreign to the human body might also elicit
treatment-neutralizing antibodies and/or potentially dangerous
allergic responses by cancer patients. One approach to avoid
generating deleterious anti-ACP immune responses is to use
peptides that are of human origin or to co-administer foreign
ACPs with immunosuppressive drugs. Alternatively, immuno-
genic ACPs could be encapsulated in liposomes engineered to
deliver their cargo to tumor sites, thereby minimizing the
opportunity to develop anti-ACP immunity. Cost is an additional
obstacle that will need to be overcome before ACPs can be
employed in cancer treatment. Although the cost of isolating
naturally occurringACPs or producing synthetic ACPs currently
exceeds that of manufacturing conventional chemotherapeutic
agents, massive investment by pharmaceutical companies in the
development of ACPs as cancer therapeutics will inevitably
result in economies of scale and innovative strategies for ACP
isolation/synthesis. In the relatively near future, AMPs that have
been optimized for anticancer activity may be an economically
viable and therapeutically superior alternative to the current
generation of chemotherapeutic drugs.
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